Anika Therapeutics, Inc.
ANIK
$9.05
$0.688.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -8.15% | -9.83% | 1,155.61% | -6.54% | -30.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.15% | -9.83% | 1,155.61% | -6.54% | -30.65% |
| Cost of Revenue | 35.38% | 14.33% | 248.42% | 136.56% | -33.24% |
| Gross Profit | -29.90% | -22.63% | 207.14% | -94.40% | -29.28% |
| SG&A Expenses | -21.69% | -14.37% | 172.65% | -23.02% | -34.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.41% | -3.41% | 211.24% | 31.57% | -32.13% |
| Operating Income | -130.94% | -71.02% | -100.40% | -259.75% | 50.15% |
| Income Before Tax | -226.42% | -102.25% | -99.85% | -292.26% | 60.42% |
| Income Tax Expenses | -48.64% | 106.98% | -72.11% | 598.27% | 503.04% |
| Earnings from Continuing Operations | -82.88% | -102.35% | -115.32% | -354.96% | 7.30% |
| Earnings from Discontinued Operations | -72.40% | 64.23% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4,411.36% | -7.95% | 65.29% | -354.96% | 96.79% |
| EBIT | -130.94% | -71.02% | -100.40% | -259.75% | 50.15% |
| EBITDA | -1,214.52% | -509.05% | -92.62% | -571.63% | 406.17% |
| EPS Basic | -4,584.75% | -10.97% | 65.11% | -350.90% | 96.84% |
| Normalized Basic EPS | -237.11% | -108.00% | -97.44% | -286.04% | 60.80% |
| EPS Diluted | -4,703.39% | -12.02% | 65.11% | -351.11% | 96.89% |
| Normalized Diluted EPS | -234.05% | -108.00% | -97.45% | -286.04% | 60.87% |
| Average Basic Shares Outstanding | -3.20% | -2.73% | -0.54% | 0.91% | 1.03% |
| Average Diluted Shares Outstanding | -2.28% | -2.73% | -0.22% | 0.91% | 1.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |